Live Feeds
● TRACKER Updated 18d ago · 29 sources tracked

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

Moderna shares have surged over 650% year-to-date as the company pivots from COVID-19 products toward oncology. Positive Phase 3 results for its personalized mRNA cancer vaccine, developed with Merck and combined with Keytruda, led to the company's addition to the Nasdaq-100 Index. Despite this rally, some analysts argue the current stock price overly prices in future success due to a high Price-To-Sales ratio and massive losses. The company now awaits the release of full data and the ESMO annual meeting.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (31)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna's stock has risen more than 650% this year.
  • ✓ Moderna is developing a personalized cancer vaccine in partnership with Merck.
🛡️ Source Corroboration: 29 independent reporting domains (80% confidence) ⏱ Read time: ~2 min

What changed

Moderna reported positive Phase 3 data for its cancer vaccine and was subsequently added to the Nasdaq-100 Index.

Live updates

  1. Moderna Joins Nasdaq-100 Following Positive Phase 3 Cancer Vaccine Data

    Moderna shares have surged over 650% year-to-date as the company pivots from COVID-19 products toward oncology. Positive Phase 3 results for its personalized mRNA cancer vaccine, developed with Merck and combined with Keytruda, led to the company's addition to the Nasdaq-100 Index. Despite this rally, some analysts argue the current stock price overly prices in future success due to a high Price-To-Sales ratio and massive losses. The company now awaits the release of full data and the ESMO annual meeting.

    Why it matters

    The stock's growth follows reports of a National Institutes of Health push to accelerate cancer vaccine development. Moderna's partnership with Merck focuses on a personalized approach to treat melanoma. This shift is intended to diversify the company's revenue streams beyond the pandemic market.

    What is confirmed

    • Moderna's stock has risen more than 650% this year.
    • Moderna is developing a personalized cancer vaccine in partnership with Merck.

    Still unconfirmed

    • Positive Phase 3 results for the vaccine combined with Keytruda are reshaping the oncology pipeline narrative.

    What to watch next

    • The ESMO annual meeting
    • The release of full Phase 3 trial data
    Sources used for this update (3)
    1. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    2. finance.yahoo.com — Phase 3 Cancer Vaccine Success Could Change The Case For ...
    3. longbridge.com — Amid the "Cancer Vaccine" Fever, Moderna's Stock Hits New ...
    confidence 80%

  2. Moderna Shares Surge on NIH-Backed Cancer Vaccine Initiative

    Moderna stock rose 14.2% on October 9 following reports that the NIH plans a COVID-style push to accelerate cancer vaccine development. The company has seen its shares climb more than 650% this year amid excitement over its oncology pipeline. While the stock has rallied, some analysts maintain price targets well below current levels. Moderna is currently preparing for Phase 3 melanoma trial results in partnership with Merck.

    Why it matters

    The NIH initiative aims to replicate the rapid development timelines used for COVID-19 vaccines to treat cancer. This effort follows a 175% stock increase in the third quarter. Moderna faces competition from BioNTech, which is moving oncology programs into late-stage trials.

    What is confirmed

    • Moderna stock surged 14.2% on October 9.
    • The NIH plans an initiative to accelerate cancer vaccine development.
    • Moderna shares have increased more than 650% this year.

    Still unconfirmed

    • BioNTech oncology programs are entering late-stage clinical trials.

    What to watch next

    • Phase 3 melanoma trial results from Moderna and Merck
    • Updates on NIH funding and timelines for the cancer vaccine push
    Sources used for this update (4)
    1. finance.yahoo.com — Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines
    2. www.tikr.com — Moderna Stock Soared 14% as NIH Plans COVID-Style Push for ...
    3. www.fool.com — Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
    4. finance.yahoo.com — Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too ...
    confidence 90%

  3. Moderna Stock Jumps on Cancer Vaccine Hopes and Nasdaq-100 Inclusion

    Moderna shares are up, fueled by positive mRNA pipeline data, an upcoming Nasdaq-100 index inclusion, and a planned national effort to accelerate cancer vaccine development. The stock previously soared 175 percent in the third quarter, driven by growth prospects from its combined therapy candidate for skin cancer. Moderna's mRNA cancer vaccine is getting ready for its next big test.

    Why it matters

    Moderna's recent stock gains occur even as major financial institutions issue valuation downgrades. The company's mRNA pipeline data has fueled investor optimism, positioning Moderna as a primary beneficiary of the planned national effort to accelerate cancer vaccine development.

    What is confirmed

    • Moderna Inc. stocks have been trading up by 10.71 percent after promising mRNA clinical trial data fueled investor optimism.
    • Moderna stock jumped 14 percent to a 52-week high following Nasdaq-100 inclusion and NIH cancer vaccine push.
    • Moderna shares climbed 4.78 percent following positive mRNA pipeline data and an upcoming Nasdaq-100 index inclusion.
    • The stock previously soared 175 percent in the third quarter, fueled by growth prospects from its combined therapy candidate for treating the most common type of skin cancer.

    Still unconfirmed

    • caution is warranted in playing MRNA shares at current levels

    What to watch next

    • Moderna's next mRNA cancer vaccine test results
    • Nasdaq-100 index inclusion
    • NIH cancer vaccine development initiative updates
    Sources used for this update (4)
    1. stockstotrade.com — MRNA Stock Jumps As Nasdaq-100 Inclusion Meets Oncology Push
    2. www.thecorequant.com — Why Moderna (NASDAQ:MRNA) Stock Jumped 14% to a 52-Week High ...
    3. finance.yahoo.com — Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine ...
    4. stockstotrade.com — MRNA Stock Surges As Cancer Vaccine Hopes And Nasdaq-100 Nod Align
    confidence 75%

  4. Moderna Stock Climbs on Cancer Vaccine Progress and Nasdaq Inclusion

    Moderna shares climbed 4.78 percent following positive mRNA pipeline data and an upcoming Nasdaq-100 index inclusion. The stock previously soared 175 percent in the third quarter, fueled by growth prospects from its combined therapy candidate for treating the most common type of skin cancer. Additionally, the stock popped 9 percent after reports detailed a planned national effort to accelerate cancer vaccine development, positioning the biotech firm as a primary beneficiary. These gains occur even as major financial institutions issue valuation downgrades.

    Why it matters

    Moderna shares reached a four-year high amid heightened investor optimism surrounding its personalized cancer vaccine, intismeran, which is co-developed with Merck. The company ranked as the second top-performing stock in the United States market during the third quarter. The momentum builds on extensive rallies throughout 2026, driven largely by clinical pipeline shifts and index repositioning.

    What is confirmed

    • Moderna shares rose 4.78 percent due to upbeat mRNA pipeline data.
    • Moderna ranked as the second top-performing stock in the US market in the third quarter.
    • The company is set to join the Nasdaq-100 index.

    Still unconfirmed

    • Lawsuits are beginning against individuals involved with COVID-19 vaccines.

    What to watch next

    • Full data readout for the intismeran personalized cancer vaccine
    • Moderna's official entry into the Nasdaq-100 index
    Sources used for this update (4)
    1. stockstotrade.com — MRNA Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Shift Momentum
    2. finance.yahoo.com — Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
    3. usawatchdog.com — Lawsuits Begin for CV19 Vaccine Criminals – Nic Hulscher | Greg Hunter’s USAWatchdog
    4. finance.yahoo.com — Moderna stock hits 4-year high on planned national cancer vaccine effort
    confidence 95%

  5. Moderna Shares Rise as Market Awaits Full Cancer Vaccine Data

    Moderna stock rose 8% on October 5 as investors await the full data readout for intismeran, its personalized cancer vaccine co-developed with Merck. The stock has surged nearly 600% in 2026, with a 202% increase since August 18. Despite this growth, Citigroup and Bank of America have issued downgrades that raise questions about the company's valuation. Moderna is also preparing to rejoin the Nasdaq-100 on October 9, replacing Warner Bros. Discovery.

    Why it matters

    The rally follows a Phase 3 trial for melanoma that met its primary endpoint. This vaccine uses mRNA technology to target cancer, marking a shift from the company's primary focus on infectious diseases. The upcoming Nasdaq-100 inclusion signals a return to a major market index.

    What is confirmed

    • Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before the market opens on October 9.
    • Moderna stock has surged nearly 600% in 2026.
    • The company is co-developing the experimental cancer vaccine intismeran.

    Still unconfirmed

    • Moderna stock rose 8% on October 5 as a full melanoma readout nears.
    • Citigroup and Bank of America have downgraded Moderna stock.
    • Moderna shares have soared 202% since August 18.

    What to watch next

    • Release of the complete melanoma trial data to the market
    • Moderna's official entry into the Nasdaq-100 on October 9
    Sources used for this update (4)
    1. 247wallst.com — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
    2. finance.yahoo.com — MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail ...
    3. www.gurufocus.com — Moderna (MRNA) Shares Surge on Cancer Vaccine Optimism ...
    4. stockminded.com — Moderna Stock Has Exploded Higher in 2026 – Is the Rally ...
    confidence 90%

  6. Moderna Lands Nasdaq-100 Spot After Vaccine Trial Success

    Moderna shares have surged following trial success for its personalized cancer vaccine, intismeran autogene, developed alongside Merck. The Phase 3 INTerpath-001 trial met its primary endpoint in melanoma. Full data was presented earlier this month at the European Society for Medical Oncology Congress 2026. The stock is up over 550% in 2026. Additionally, the company is scheduled to replace Warner Bros. Discovery in the Nasdaq-100 before markets open on October 9. Meanwhile, Moderna is holding talks with Middle East partners regarding investment and manufacturing cooperation.

    Why it matters

    The recent market momentum highlights Moderna's corporate transition beyond COVID-19 products into an expanded biotechnology and oncology platform. Positive results from the late-stage INTerpath-001 trial combining the mRNA vaccine with Keytruda have driven retail and institutional interest. Talks regarding Middle East manufacturing cooperation further indicate the company's efforts to scale its global footprint.

    What is confirmed

    • Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on October 9.
    • The Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint in melanoma.
    • Full trial data was presented at the European Society for Medical Oncology Congress 2026.

    Still unconfirmed

    • Moderna is in talks with Middle East partners concerning potential investment and manufacturing cooperation.

    What to watch next

    • The official addition of Moderna to the Nasdaq-100 index prior to market opening on October 9.
    • Further updates regarding investment and manufacturing agreements with Middle East partners.
    Sources used for this update (6)
    1. stockanalysis.com — Moderna (MRNA) Stock Price & Overview
    2. finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
    3. www.fool.com — Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
    4. stocktwits.com — SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
    5. stocktwits.com — DAL Stock In Focus: Musk-Bastian Feud Over Starlink Escalates As United, American Court Delta Flyers
    6. labels.modernatx.com — Moderna
    confidence 100%

  7. Moderna Stock Climbs as Cancer Vaccine Pipeline Advances

    Moderna shares have climbed as investors respond to the company's shift toward a diversified biotechnology platform beyond COVID-19 products. Chief Executive Officer Bancel emphasized the expanding pipeline, which includes the personalized cancer vaccine intismeran autogene, rare-disease therapeutics, and new respiratory approvals. Market activity has intensified following disclosures that the vaccine, combined with Keytruda, extended melanoma-free survival in a late-stage trial. Analysts remain divided on the stock's valuation as the market awaits upcoming oncology presentations.

    Why it matters

    The company reported annual revenue of $1.94 billion alongside a net loss as it pivots its business model. Wall Street sentiment remains mixed, creating a wide gap between current trading levels and consensus price targets. The upcoming data presentation at the ESMO Congress will serve as a crucial test for the commercial viability of the oncology portfolio.

    What is confirmed

    • Moderna stock jumped 7% on Thursday, September 24, closing at $195.
    • The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120.
    • Chief Executive Officer Bancel stated the company is an mRNA platform rather than solely a Covid vaccine maker.
    • Moderna reported $1.94 billion in annual revenue and a net loss.

    Still unconfirmed

    • Intismeran autogene Phase 3 melanoma data is due at ESMO on October 24.

    What to watch next

    • The presentation of intismeran autogene Phase 3 melanoma data at the ESMO Congress on October 24.
    • Further updates regarding respiratory approvals and rare-disease pipeline expansion.
    Sources used for this update (15)
    1. www.marketbeat.com — MRNA News Today | Why did Moderna stock go up today? - MarketBeat
    2. www.marketbeat.com — Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
    3. finance.yahoo.com — Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO ...
    4. coincentral.com — Moderna (MRNA) Stock Hits 52-Week High on Cancer Vaccine ...
    5. www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Up by 5.91% on Sep 24: What ...
    6. stocktwits.com — Nasdaq, S&P 500 Futures Fall As Oil Spikes On Trump’s Snub To Iran: MU, NVDA, SKHY, SPCX, NIO Stocks In....
    7. www.modernatx.com — Pioneering mRNA technology - Moderna
    8. en.wikipedia.org — Moderna - Wikipedia
    9. www.modernatx.com — Company Culture - Moderna
    10. finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
    11. www.cnn.com — Moderna and Merck say melanoma vaccine succeeded in large trial
    12. www.cnbc.com — Moderna, Merck cancer vaccine shows initial late-stage melanoma...
    confidence 90%

  8. Moderna Stock Hits New High Ahead of Cancer Vaccine Data Release

    Moderna shares rose between 10% and 12% to reach a new high as the company prepares to present late-breaking data from a key melanoma trial at the ESMO Congress 2026. The surge comes as investors anticipate pipeline updates this week regarding the company's mRNA cancer vaccine. Market activity reflects growing interest in the efficacy of the vaccine's next testing phase and the results of the melanoma study.

    Why it matters

    Moderna is expanding its mRNA platform beyond COVID-19 into oncology. The ESMO Congress is a major venue for oncology research where clinical trial results can significantly impact regulatory paths and market valuation.

    What is confirmed

    • Moderna stock reached a new high with gains reported between 10% and 12%.
    • Moderna will present late-breaking data from a key melanoma trial at the ESMO Congress 2026.
    • The company is expected to provide pipeline updates this week.

    What to watch next

    • The specific clinical trial results presented at the ESMO Congress 2026
    • Official pipeline update disclosures from Moderna this week
    Sources used for this update (7)
    1. barrons.com — Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
    2. Seeking Alpha — Moderna rallies 12% to set new high (MRNA:NASDAQ)
    3. Moomoo — Moderna Stock Jumps 10%+. Its MRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
    4. Yahoo Finance — Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week
    5. Investing.com — Why is Moderna stock surging today?
    6. Yahoo Finance — Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’
    7. Yahoo Finance — Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community